Multiphasic 68Ga-Psma Pet/Ct in the Detection of Early Recurrence in Prostate Cancer Patients With a Psa Level of Less Than 1 Ng/Ml: A Prospective Study of 135 Patients Publisher Pubmed



Beheshti M^{1, 2, 3} ; Manafifarid R⁴ ; Geinitz H⁵ ; Vali R⁶ ; Loidl W⁷ ; Mottaghy FM^{1, 8} ; Langsteger W³
Source: Journal of Nuclear Medicine Published:2020

Abstract

The main objective of this prospective study was to determine the impact of multiphasic acquisition of 68Ga-PSMA PET/CT in the detection of recurrent prostate cancer in the early stage of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/mL. Also, 68Ga-PSMA PET/CT positivity was correlated with clinical parameters for the assessment of predictive markers. Methods: A prospective monocentric study was conducted on 135 prostate cancer patients with biochemical recurrence and a PSA level of less than 1 ng/mL. All patients had undergone initial prostatectomy, with additional radiation therapy in 19.3% of patients and androgen-deprivation therapy in 7.4%. The patients underwent dynamic acquisitions from the prostate bed (1–8 min after injection), standard whole-body acquisitions (60 min after injection), and limited-bed-position delayed acquisitions (120–150 min after injection). The studies were reviewed by 2 board-certified nuclear medicine specialists, independently. A combination of visual and semiquantitative analyses and correlation with morphologic (e.g., MRI) or clinical follow-up findings was used for the final interpretation of lesions as benign or malignant. 68Ga-prostate-specific membrane antigen (PSMA) PET/CT positivity was also correlated with primary clinical findings. Results: Incorporating the information from all phases, we were able to detect 116 lesions in 49.6% of patients (22 local recurrences, 63 lymph nodes, and 31 distant metastases). The detection rates were 31.8%, 44.9%, and 71.4% for PSA, 0.2 ng/mL, 0.2 # PSA, 0.5, and 0.5 # PSA, 1, respectively. Additional dynamic or delayed phases resulted in better determination of equivocal lesions and a higher diagnostic performance in 25.9% of patients. Stand-alone dynamic and delayed images led to better interpretation of equivocal findings in the prostate bed (31.4%) and in other lesions (lymph node or bone) (20%), respectively. Conclusion: 68Ga-PSMA PET/CT showed promise for early detection of recurrent disease in patients with a PSA level of 0.5–1.0 ng/mL. However, it showed limited value in patients with a PSA level of less than 0.5 ng/mL. Multiphasic 68Ga-PSMA PET/CT led to a better determination of equivocal findings. Although dynamic images may provide helpful information for assessment of the prostate bed, delayed acquisitions seem to have a greater impact in clarifying equivocal findings. COPYRIGHT © 2020 by the Society of Nuclear Medicine and Molecular Imaging.